Skin Peptides

A naturally occurring copper-binding peptide studied for skin regeneration, wound healing, and anti-aging effects.

A tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties.

A human antimicrobial peptide studied for innate immunity, wound healing, and biofilm disruption.

A senolytic peptide designed to selectively clear senescent cells by disrupting FOXO4-p53 interaction.

A melanocortin receptor agonist FDA-approved (in Europe) for preventing phototoxicity in erythropoietic protoporphyria.

A cosmetic peptide studied for reducing the appearance of wrinkles by modulating muscle contraction signaling.

A multi-peptide blend combining BPC-157, TB-500, GHK-Cu, and KPV for comprehensive tissue repair and anti-inflammatory support.

A multi-peptide blend of BPC-157, TB-500, and GHK-Cu formulated for tissue repair and skin rejuvenation.

The first FDA-approved targeted oral macrocyclic peptide — an IL-23 receptor antagonist for moderate-to-severe plaque psoriasis, marking a new era for oral peptide therapeutics.

Difelikefalin (Korsuva in the U.S., Kapruvia in Europe) is a synthetic tetrapeptide built entirely from D-amino acids - D-Phe-D-Phe-D-Leu-D-Lys capped with a 4-aminopiperidine-4-carboxylic acid - that acts as a selective agonist at the kappa opioid receptor. Its defining property is what it cannot do: the molecule is hydrophilic and bulky enough that it does not meaningfully cross the blood-brain barrier, so it reaches kappa receptors on peripheral sensory nerve endings, keratinocytes and immune cells while leaving the central kappa receptors that produce dysphoria and hallucinations largely untouched. It has no activity at the mu opioid receptor, so it carries neither euphoria nor respiratory depression. In the Phase 3 KALM-1 and KALM-2 trials in hemodialysis patients with moderate-to-severe chronic-kidney-disease-associated pruritus, roughly 40-51% of difelikefalin-treated patients achieved a clinically meaningful (>=3-point) reduction on the 10-point Worst Itching Intensity NRS at 12 weeks versus roughly 20-28% on placebo. The FDA approved intravenous difelikefalin in August 2021; the EU approved it as Kapruvia in April 2022.